Investment Thesis
Silo Pharma is a pre-revenue stage pharmaceutical company with severe fundamental deterioration: $18K quarterly revenue against $1.6M operating losses, negative gross margins, and $822.6K quarterly cash burn. With $3.9M cash and current burn rate, the company has approximately 19 months of runway before requiring dilutive financing or restructuring.
Strengths
- Zero debt on balance sheet with positive $5.7M stockholders equity
- Strong current ratio (9.65x) and quick ratio (9.57x) provide near-term liquidity
- Cash position of $3.9M covers operational needs for several quarters
Risks
- Near-zero revenue ($18K) with no demonstrated commercialization progress in pharma sector
- Negative gross margin (-14.8%) indicates product/service economics are not viable at current scale
- Quarterly cash burn of $822.6K creates unsustainable depletion of cash reserves with limited runway
- Operating losses of $1.6M per quarter against minimal revenue demonstrates no profitability pathway
- No insider trading activity and lack of revenue traction suggest management confidence concerns
- Pharmaceutical development requires multi-year timelines; current burn rate incompatible with industry requirements
Key Metrics to Watch
- Quarterly revenue growth and customer acquisition metrics
- Monthly cash burn rate and revised runway analysis
- Operating expenses and cost structure changes
- Any clinical trial milestones or FDA approval announcements
- Financing activities and dilution from capital raises
Financial Metrics
Revenue
18.0K
Net Income
-1.6M
EPS (Diluted)
$-0.12
Free Cash Flow
-822.6K
Total Assets
7.0M
Cash
3.9M
Profitability Ratios
Gross Margin
-14.8%
Operating Margin
-8,846.4%
Net Margin
-9,137.5%
ROE
-29.0%
ROA
-23.5%
FCF Margin
-4,563.5%
Balance Sheet & Liquidity
Current Ratio
9.65x
Quick Ratio
9.57x
Debt/Equity
0.00x
Debt/Assets
19.0%
Interest Coverage
-852.76x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T07:35:31.056751 |
Data as of: 2026-03-31 |
Powered by Claude AI